Fairvalue-Calculator Fairvalue-Calculator
EN DE

CellBion Co (308430) Fair Value & Analysis

Healthcare · KR · Market cap 228B KRW

Price16,720 KRW
Fair Value5,327 KRW
Upside-68.1%
Quality95/100
Evidence: Low Range 3,996 KRW – 6,659 KRW

Fair value as of: Jun 24, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

CellBion Co (308430) currently trades at 16,720 KRW, while our model-based Fair Value estimate is 5,327 KRW — implying the stock looks roughly 68.1% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

CellBion Co., Ltd. engages in the research and development of radiopharmaceutical products. Its clinical stage pipeline includes 177Lu-PSMA-DGUL, indicated for prostate cancer radiotherapy, currently under Phase 2 clinical stage; 225Ac-Antibody, indicated for multiple cancer types, currently under pre-clinical stage; 225Ac-DGUL, indicated for prostate cancer radiotherapy, currently under pre-clinical stage; 68Ga-Nota-MSA, indicated for cardiovascular disease diagnosis, currently under Phase 2 clinical stage; 99mTc-MSA-ICG, indicated for lymphoscintigraphy SLN mapping, currently under Phase 1 clinical stage; and 68Ga-NGUL, indicated for prostate cancer diagnosis, currently under Phase 2 clinical stage. It is involved in the development of preclinical stage pipeline comprising 68 Ga-FAP, indicated for solid tumors diagnosis; 225 Ac-FAP, indicated for solid tumors radiotherapy; and peptide-based radioligand therapy and antibody-radionuclide conjugates for undisclosed indications. CellB…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is CellBion Co (308430) undervalued?
As of Jun 24, 2026, our model estimates a fair value of 5,327 KRW versus a price of 16,720 KRW — about −68% (overvalued). Model-based estimate, not financial advice.
What is the fair value of 308430?
Our 21-model fair value for CellBion Co is 5,327 KRW (as of Jun 24, 2026), built from audited fundamentals. The current price is 16,720 KRW.
What is the quality score of 308430?
CellBion Co has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.